Related Experiment Video
Updated: Jan 30, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
[Antithrombotic treatment in acute coronary syndrome and atrial fibrillation]
H Darius1, G Görge2, M Spiecker3
1Klinik für Kardiologie, Angiologie, Nephrologie und konservative Intensivmedizin, Vivantes Klinikum Neukölln, Rudower Str. 48, 12351, Berlin, Deutschland. harald.darius@vivantes.de.
Insights
Non-vitamin K oral anticoagulants plus a single antiplatelet agent are safer than triple therapy for patients with atrial fibrillation and acute coronary syndrome. This approach reduces bleeding complications without increasing stroke or cardiac ischemia risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Increasing prevalence of atrial fibrillation (AF) and need for oral anticoagulation (OAC) in aging populations.
- Rising incidence of patients requiring both OAC for stroke prevention and dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI).
- Traditional triple therapy (TT) for these patients has shown higher bleeding risks without proven efficacy benefits compared to other strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of non-vitamin K oral anticoagulants (NOACs) combined with antiplatelet therapy in patients with AF and ACS/PCI.
- To compare NOAC-based strategies against traditional vitamin K antagonist (VKA) therapies and DAPT regimens.
- To assess the bleeding risk and thrombotic events associated with different antithrombotic strategies.
Main Methods:
- Review of prospective and randomized studies investigating all four approved NOACs for stroke prevention in AF.
- Comparison of NOACs plus single antiplatelet therapy versus VKA plus single antiplatelet therapy, specifically excluding DAPT in some trials.
- Analysis of published trial data (e.g., PIONEER AF-PCI, RE-DUAL PCI) and ongoing investigations (e.g., AUGUSTUS, ENTRUST-AF PCI).
Main Results:
- NOAC plus a single antiplatelet agent demonstrates superiority over TT in terms of reduced bleeding complications.
- No significant increase in stroke or cardiac ischemia events observed with NOAC plus single antiplatelet therapy compared to TT.
- International guidelines now support NOAC plus single antiplatelet therapy for patients with high bleeding risk, deeming TT unnecessary for most.
Conclusions:
- Triple therapy is no longer indicated for the majority of patients with AF who have undergone ACS or PCI.
- Non-vitamin K oral anticoagulants combined with a single antiplatelet agent represent a safer and effective alternative to triple therapy.
- Current evidence supports individualized antithrombotic strategies prioritizing bleeding risk reduction in AF patients with coronary indications.
Abstract:
The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and indications for oral anticoagulation (OAC) for the prevention of stroke, who need dual antiplatelet treatment (DAPT) with acetylsalicylic acid (ASA) plus a P2Y12 inhibitor because of an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is also increasing. In the past these patients received a triple therapy (TT) for 3-12 months. This TT has never been studied for efficacy; however, the rate of bleeding complications in comparison to a simple OAC or DAPT is significantly higher. Registries and smaller trials showed that DAPT with an OAC plus a platelet inhibitor may be sufficient to prevent stroke and stent thromboses/myocardial infarctions. These questions were investigated in various prospective and randomized studies involving all four non-vitamin K oral anticoagulants (NOAC) approved for stroke prevention in AF. The NOACs were tested against vitamin K antagonists (VKA) involving single antiplatelet therapy without using DAPT. The trials with rivaroxaban (PIONEER AF-PCI) and dabigatran (RE-DUAL PCI) have already been published but the investigations involving apixaban (AUGUSTUS) and edoxaban (ENTRUST-AF PCI) are still ongoing. The current status is that a NOAC plus a single antiplatelet agent, mostly clopidogrel, is superior to TT with VKA with respect to bleeding complications without any obvious disadvantage due to increases in stroke cases or cardiac ischemia. The international guidelines already permit treatment without TT in cases where the bleeding risk is prevalent. In this situation it is recommended to prescribe a NOAC plus a single antiplatelet therapy. Thus, TT no longer seems to be indicated for most patients with AF and after ACS or PCI.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...